Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca BD Head Says More Out-Licensing, Divestment Expected In 2016

This article was originally published in Scrip

Executive Summary

AstraZeneca PLC says it remains committed to developing medicines across small molecules, biologics, vaccines, protein engineering and devices and that's what its future targeted business development strategy will pursue.


Related Content

Biopharma Quarterly Dealmaking Statistics, Q2 2016
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds